Advanced In Vivo Precision
Abstract: The present disclosure relates to compositions of matter and methods used to activate effector nucleic acids and effector targets in vivo via a CRISPR-based cascade system. The compositions and methods achieve non-specific delivery of cascade system components to cells yet the cascade system works in a cell-specific manner.
Swanson Reed Patent of the Month: March 2026
We are proud to announce that VedaBio, Inc. has been awarded Swanson Reed’s Patent of the Month in the Biotechnology, Chemical Engineering, and Nanotechnology category. This recognition is reserved for inventions that represent a significant leap forward in scientific capability, and VedaBio’s CRISPR-based cascade system is a quintessential example of such excellence. By solving one of the most persistent challenges in gene therapy—achieving cell-specific activation from non-specific delivery—this patent sets a new benchmark for therapeutic safety and efficacy.
The ingenuity of this system lies in its cascade architecture, which allows for a controlled, multi-step activation process. In an industry where off-target effects are a primary concern, VedaBio has engineered a sophisticated biological logic gate that ensures therapeutics are only switched on when they reach the intended cellular environment. This level of control is a monumental achievement in chemical engineering and nanotechnology, providing a programmable platform that can be adapted for a wide array of genetic diseases.
VedaBio’s contribution underscores the rapid evolution of CRISPR technology beyond simple editing. This patent moves the needle toward holistic in vivo management of disease, demonstrating an outstanding integration of molecular biology and precision delivery. Swanson Reed recognizes this patent not just for its technical complexity, but for its potential to transform patient outcomes across the global biotech landscape, making it a well-deserved recipient of the Patent of the Month honors.
R&D Tax Credit Eligibility (USA)
The development of this CRISPR-based cascade system likely qualifies for the U.S. Research and Development Tax Credit under IRC Section 41. To meet the Four-Part Test, the project must demonstrate:
- Permitted Purpose: The activity must relate to developing a new or improved function, performance, reliability, or quality of a business component (the therapeutic system).
- Elimination of Uncertainty: The project must intend to discover information to eliminate uncertainty concerning the capability, method, or appropriate design of the system.
- Process of Experimentation: Substantially all activities must constitute a process of experimentation involving the evaluation of alternatives and systematic testing.
- Technological in Nature: The research must rely on principles of physical, biological, engineering, or computer science.
Practical R&D Application Examples
Below are three practical applications of this patent’s development that would meet the R&D Tax Credit rules:
- Design and Iteration of Molecular Logic Gates: The iterative process of designing the specific CRISPR guide RNAs and effector sequences to ensure they only trigger in the presence of specific cellular biomarkers involves significant Process of Experimentation to eliminate design uncertainty.
- Nanotechnology Delivery Vehicle Optimization: Researching and testing different lipid nanoparticles or chemical carriers to achieve non-specific delivery while maintaining the stability of the CRISPR components requires biological and chemical engineering expertise to overcome technical uncertainties.
- In Vivo Safety and Efficacy Modeling: Conducting systematic laboratory testing and clinical trials to verify that the cascade does not activate in non-target cells involves rigorous scientific experimentation and data analysis to meet the Technological in Nature and Permitted Purpose requirements.
